Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Short Interest Update

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) was the recipient of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 2,710,000 shares, an increase of 1,180.7% from the January 15th total of 211,600 shares. Currently, 25.5% of the company’s stock are short sold. Based on an average daily volume of 17,180,000 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Trading of Hepion Pharmaceuticals

A hedge fund recently bought a new stake in Hepion Pharmaceuticals stock. Anson Funds Management LP purchased a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned 3.33% of Hepion Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 17.24% of the company’s stock.

Hepion Pharmaceuticals Stock Performance

Shares of HEPA stock opened at $0.20 on Thursday. Hepion Pharmaceuticals has a 1 year low of $0.12 and a 1 year high of $3.49. The stock’s 50-day moving average is $0.42 and its two-hundred day moving average is $0.59. The firm has a market cap of $1.40 million, a price-to-earnings ratio of -0.05 and a beta of 1.65.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.